1
|
Ahmed Y, Ali ZY, Mohamed MA, Rashed LA, Mohamed EK. Impact of combined therapy of mesenchymal stem cells and sitagliptin on a metabolic syndrome rat model. J Diabetes Metab Disord 2021; 20:551-560. [PMID: 34222076 DOI: 10.1007/s40200-021-00778-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Accepted: 03/20/2021] [Indexed: 12/20/2022]
Abstract
Background Emerging evidence suggests that mesenchymal stem cells (MSCs) have many anti-inflammatory and regenerative properties, which makes it a suitable candidate for the treatment of many diseases including metabolic syndrome (MetS). However, a major difficulty with stem cell therapy is to maintain cell viability, properties and function after implantation in vivo. This study aims to test the hypothesis that the combined therapy of MSCs and sitagliptin can effectively ameliorate MetS complications induced by high-fat and high-fructose diet (HFFD) in rats. Methods Rats were fed either standard diet (Control group) or HFFD. After 3 months, a group of HFFD animals was injected by a single dose of MSCs, another group received a daily oral dose of 10 mg/kg b.w. of sitagliptin, and the third group received the combined therapy of MSCs + sitagliptin for 1 month. Results Both MSCs and sitagliptin restored insulin sensitivity and reduced the HOMA-IR value in HFFD rats. The hepatic IRS-1 and Akt at both gene and protein levels, as well as the hepatic protein levels of IR and GLUT4 were improved. Downregulation of CHOP and NF-κB and upregulation of hepatic HO-1 expression and activity were also reported. Although MSCs and sitagliptin as monotherapy lead to remarkable effects, the dual application revealed the best results. Interestingly, histological findings confirmed these protective effects of the combined therapy against MetS complications. Conclusion Combined therapy of MSCs and sitagliptin can efficiently ameliorate the insulin resistance and promote the regeneration of hepatocytes in the metabolic syndrome rat model.
Collapse
Affiliation(s)
- Yossra Ahmed
- King Saud University, Riyadh, Saudi Arabia.,Faculty of Science, Al-Azhar University (Girls Branch), Cairo, Egypt
| | - Zeinab Y Ali
- National Organization of Drug Control and Research, Cairo, Egypt
| | - Mona A Mohamed
- Biochemistry Unit, Chemistry Department, Faculty of Science, Al-Azhar University (Girls Branch), Cairo, Egypt
| | - Laila A Rashed
- Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Ehsan K Mohamed
- National Organization of Drug Control and Research, Cairo, Egypt
| |
Collapse
|
2
|
Shree N, Venkategowda S, Venkatranganna MV, Datta I, Bhonde RR. Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation. Int J Obes (Lond) 2019; 43:2107-2118. [PMID: 31462691 DOI: 10.1038/s41366-019-0438-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 07/06/2019] [Accepted: 07/22/2019] [Indexed: 01/05/2023]
Abstract
OBJECTIVE Obesity induced metabolic dysregulation results in cluster of chronic conditions mainly hyperglycemia, hyperinsulinemia, dyslipidemia, diabetes, cardiovascular complications and insulin resistance. To investigate the effect of i.m. injection of human adipose tissue derived mesenchymal stem cells and its secretome in correcting obesity induced metabolic dysregulation in high fat diet fed obese model of mice and understand its mechanism of action. SUBJECTS We injected human adipose tissue derived mesenchymal stem cells (ADMSCs) suspension (CS), conditioned medium (CM) and the cell lysate (CL) intramuscularly in high fat diet (HFD)-induced C57BL/6 mice. Metformin was used as a positive control. ADMSCs were traced in vivo for its bio distribution after injection at different time points. RESULTS ADMSCs-treated mice exhibited remarkable decrease in insulin resistance as quantified by HOMA-IR and triglyceride glucose index with concomitant decrease in oxidized LDL and IL6 as compared with the untreated control. CS injection showed improvement in glucose tolerance and reduction in fatty infiltration in the liver, macrophage infiltration in adipose and hypertrophy of the islets resulting from HFD. Upregulation of miRNA-206, MyoD and increase in protein content of the skeletal muscle in CS-treated mice indicates plausible mechanism of action of ADMSCs treatment in ameliorating IR in HFD mice. CONCLUSION Of all the three treatments, CS was found to be the best. ADMSCs were found to have migrated to different organs in order to bring about the correction in dysregulated metabolism induced by obesity. Our results open up a novel treatment modality for possible therapeutic usage in human subjects by employing autologous or allogeneic ADMSCs for the better management of obesity induced metabolic dysregulation.
Collapse
Affiliation(s)
- Nitya Shree
- School of Regenerative Medicine, Manipal Academy of Higher Education, Bangalore, India
| | | | | | | | - Ramesh R Bhonde
- School of Regenerative Medicine, Manipal Academy of Higher Education, Bangalore, India. .,Dr. D.Y. Patil Vidyapeeth, Pune, India.
| |
Collapse
|
3
|
Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders. Int J Mol Sci 2018; 19:ijms19092783. [PMID: 30223606 PMCID: PMC6163453 DOI: 10.3390/ijms19092783] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 09/05/2018] [Accepted: 09/14/2018] [Indexed: 02/06/2023] Open
Abstract
Diabetes is a worldwide disease which actually includes different disorders related to glucose metabolism. According to different epidemiological studies, patients affected by diabetes present a higher risk to develop both acute and chronic pancreatitis, clinical situations which, in turn, increase the risk to develop pancreatic cancer. Current therapies are able to adjust insulin levels according to blood glucose peak, but they only partly reach the goal to abrogate the consequent inflammatory milieu responsible for diabetes-related diseases. In recent years, many studies have investigated the possible use of adult mesenchymal stem cells (MSCs) as alternative therapeutic treatment for diabetes, with promising results due to the manifold properties of these cells. In this review we will critically analyze the many different uses of MSCs for both diabetes treatment and for the reduction of diabetes-related disease development, focusing on their putative molecular mechanisms.
Collapse
|
4
|
Sabadine MA, Russo TL, Luna GF, Oliveira Leal AM. Effects of mesenchymal stromal cells on type 1 diabetes mellitus rat muscles. Muscle Nerve 2018; 58:583-591. [PMID: 30028527 DOI: 10.1002/mus.26196] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 06/05/2018] [Accepted: 06/09/2018] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Type 1 diabetes mellitus (DM) causes marked skeletal muscle atrophy. Mesenchymal stromal cells (MSC) are an attractive therapy to avoid diabetic complications because of their ability to modify the microenvironment at sites of tissue injury. The objective of this study was to evaluate the effects of MSC transplantation on muscle adaptation caused by diabetes. METHODS DM was induced by streptozotocin (STZ), and the diabetic animals received systemic MSC transplantation. The von Frey test and footprint analysis were used to assess sensation and sensory motor performance, respectively. Tibialis anterior muscles were investigated by morphology; molecular markers atrogin-1/muscle RING-finger protein-1, nuclear factor κB/p38 mitogen-activated protein kinase, tumor necrosis-like weak inducer of apoptosis/fibroblast growth factor-inducible 14, myostatin, myogenic differentiation 1, and insulin-like growth factor 1 were also assessed. RESULTS MSC transplantation improved sensation and walking performance and also decreased muscle fibrosis in DM rats by modulating atrogenes but did not prevent muscle atrophy. DISCUSSION MSCs can reduce muscle and functional complications that result from type 1 DM in rats. Muscle Nerve 58: 583-591, 2018.
Collapse
Affiliation(s)
- Maria Augusta Sabadine
- Department of Medicine, Federal University of São Carlos, Rodovia Washington Luís, Km 235 - SP310, CEP: 13565-905, São Carlos/SP, Brazil
| | - Thiago Luiz Russo
- Department of Physical Therapy, Federal University of São Carlos, São Carlos, SP, Brazil
| | - Genoveva Flores Luna
- Department of Medicine, Federal University of São Carlos, Rodovia Washington Luís, Km 235 - SP310, CEP: 13565-905, São Carlos/SP, Brazil
| | - Angela Merice Oliveira Leal
- Department of Medicine, Federal University of São Carlos, Rodovia Washington Luís, Km 235 - SP310, CEP: 13565-905, São Carlos/SP, Brazil
| |
Collapse
|
5
|
Deng Z, Xu H, Zhang J, Yang C, Jin L, Liu J, Song H, Chen G, Han W, Si Y. Infusion of adipose‑derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats. Mol Med Rep 2018; 17:8466-8474. [PMID: 29693163 DOI: 10.3892/mmr.2018.8901] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 03/08/2018] [Indexed: 11/06/2022] Open
Abstract
It is widely accepted that infusion of mesenchymal stem cells (MSCs) ameliorates hyperglycemia by alleviating insulin resistance in rats with type 2 diabetes mellitus (T2D). However, the detailed underlying mechanisms are not clearly defined. Mitsugumin 53 (MG53) is an E3 ligase that has recently been implicated in the aggravation of insulin resistance by promoting the ubiquitinoylation of insulin receptor substrate‑1 (IRS‑1) in skeletal muscles. It was therefore hypothesized that MG53 may be involved in MSC‑mediated therapeutic effects on insulin resistance. To test this hypothesis, in the present study, T2D rat models were induced by a high‑fat diet combined with streptozotocin administration and MSC infusion was performed four times (once every 2 weeks for 8 weeks). The therapeutic effects of MSC infusion on insulin resistance were evaluated and the effect on the expression of MG53 and insulin receptor signaling elements in skeletal muscle was also investigated by immunofluorescence staining and western blotting. The results demonstrated that MSC infusion ameliorated hyperglycemia and insulin resistance in T2D rats. Furthermore, MSC infusion inhibited MG53 elevation and reversed the decreases in glucose transporter type 4, insulin receptor, IRS‑1 and phosphorylated‑AKT levels in the skeletal muscle of T2D rats. These results indicated that MSC infusion has therapeutic effects in rats and that MG53 in skeletal muscle may be a promising novel therapeutic target protein for MSC‑mediated amelioration of insulin resistance in T2D.
Collapse
Affiliation(s)
- Zihui Deng
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Huiyan Xu
- Department of Traditional Chinese Medicine, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Jinying Zhang
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Chen Yang
- Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Liyuan Jin
- Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Jiejie Liu
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Haijing Song
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Guanghui Chen
- Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Weidong Han
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Yiling Si
- Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China
| |
Collapse
|
6
|
Orsi PR, Landim-Alvarenga FC, Justulin LA, Kaneno R, de Assis Golim M, Dos Santos DC, Creste CFZ, Oba E, Maia L, Barraviera B, Ferreira RS. A unique heterologous fibrin sealant (HFS) as a candidate biological scaffold for mesenchymal stem cells in osteoporotic rats. Stem Cell Res Ther 2017; 8:205. [PMID: 28962655 PMCID: PMC5622505 DOI: 10.1186/s13287-017-0654-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 08/27/2017] [Accepted: 08/30/2017] [Indexed: 02/07/2023] Open
Abstract
Background The injection of mesenchymal stem cells (MSCs) directly into the bone of osteoporotic (OP) patients for rapid recovery has been studied worldwide. Scaffolds associated with MSCs are used to maintain and avoid cell loss after application. A unique heterologous fibrin sealant (HFS) derived from snake venom was evaluated for the cytotoxicity of its main components and as a three-dimensional biological scaffold for MSCs to repair a critical femur defect in osteoporotic rats. Methods The cytotoxicity of HFS was assessed using a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) assay and transmission electron microscopy. The cells were cultured, characterized by flow cytometry and differentiated into the osteogenic lineage. Two-month-old rats underwent ovariectomy to induce OP. After 3 months, a 5 mm critical bone defect was made in the distal end of the rat femurs and filled with HFS; HFS + MSCs; and HFS + MSCs D (differentiated into the osteogenic lineage) to evaluate the effects. An injury control group (injury and no treatment) and blank control group (no injury and no treatment) were also included. The animals were observed at days 14 and 28 by microtomographic (micro-CT) analyses, histologic and biochemical analysis, as well as scanning electron microscopy. Results The results revealed that one of the compounds of HFS, the thrombin-like enzyme extracted from snake venom, had no cytotoxic effects on the MSCs. OP was successfully induced, as demonstrated by the significant differences in the levels of 17β-estradiol, Micro-CT analyses and alkaline phosphatase between the ovariectomized (OVX) and non-ovariectomized (NOVX) groups. The histological data revealed that at 14 days after surgery in both the OVX and NOVX animals, the HFS + CTMs and HFS + CTMsD showed a higher formation of bone cells at the site in relation to the control group (without treatment). Collagen formation was evidenced through bone neoformation in all treated and control groups. No morphological differences in the femurs of the NOVX and OVX animals were observed after the surgical procedure. Scanning electron microscopy (SEM) confirmed the histological analysis. Conclusions The new HFS composed of two non-toxic components for MSCs showed capacity to promote the recovery of the bone lesions in OVX and NOVX animals at 14 days after surgery. In addition, the HFS enabled the differentiation of MSCs into MSCs D in the group treated with HFS + MSCs. Using the MSCs and/or MSCs D together with this biopharmaceutical could potentially enable significant advances in the treatment of osteoporotic fractures. Future clinical trials will be necessary to confirm these results.
Collapse
Affiliation(s)
- Patrícia Rodrigues Orsi
- Center for the Study of Venoms and Venomous Animals (CEVAP), UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil.,Botucatu Medical School, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil
| | | | - Luis Antônio Justulin
- Botucatu Biosciences Institute, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil
| | - Ramon Kaneno
- Botucatu Biosciences Institute, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil
| | | | | | - Camila Fernanda Zorzella Creste
- Center for the Study of Venoms and Venomous Animals (CEVAP), UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil.,Botucatu Medical School, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil
| | - Eunice Oba
- College of Veterinary Medicine and Animal Husbandry (FMVZ), UNESP - Univ Estadual Paulista, Botucatu, SP, Brazil
| | - Leandro Maia
- College of Veterinary Medicine and Animal Husbandry (FMVZ), UNESP - Univ Estadual Paulista, Botucatu, SP, Brazil
| | - Benedito Barraviera
- Center for the Study of Venoms and Venomous Animals (CEVAP), UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil.,Botucatu Medical School, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil
| | - Rui Seabra Ferreira
- Center for the Study of Venoms and Venomous Animals (CEVAP), UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil. .,Botucatu Medical School, UNESP - Universidade Estadual Paulista, Botucatu, SP, Brazil.
| |
Collapse
|